GFT505‐315‐1: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis
October 31, 2016
Gastroenterology - Stomach
Principal Investigator: Stuart C Gordon, MD
The purpose of this research study is to learn more about the efficacy and safety of 120 mg daily Elafibranor.
Please contact us for a full list of criteria.